Transgene and NEC extend collaboration to develop head and neck cancer vaccine

[cafead]

via Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.

article source